MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Advanced Breast Cancer Therapies
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

898 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
898 works in the cohort · of 4,299,418page 4 of 18

Labels cover 3 of 898 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 898 of 898 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with <i>PIK3CA</i> -mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC).
Nicholas C. Turner, Seock‐Ah Im, Cristina Saura, Dejan Juric, Sibylle Loibl, Kevin Kalinsky +9 more
2025· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrityconsensus · none
20
citations
affunlabeled
Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent <i>ESR1</i> mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.
Nicholas C. Turner, Erik Mayer, Yeon Hee Park, Wolfgang Janni, X. Cynthia, Massimo Cristofanilli +14 more
2025· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
18
citations
affno abstractunlabeled
LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study
Sara A. Hurvitz, Y.H. Park, Aditya Bardia, Vanesa Quiroga, Vanesa López-Valverde, Jutta Steinseifer +4 more
2021· article· en· Annals of Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
18
citations
affno abstractunlabeled
VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial
Barbara Pistilli, Komal Jhaveri, S-A. Im, Michelino De Laurentiis, Shuhua Wang, Noelia Martínez-Jáñez +13 more
2025· article· en· Annals of Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
17
citations
affunlabeled
Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B
Sibylle Loibl, Frederik Marmé, Miguel Martín, Michael Untch, Hervé Bonnefoi, Sung‐Bae Kim +16 more
2021· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
17
citations
affunlabeled
Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13)
Gϋnter von Minckwitz, Harry D. Bear, Hervé Bonnefoi, Marco Colleoni, Karen A. Gelmon, Michael Gnant +10 more
2013· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · none
16
citations
affunlabeled
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) <i>PIK3CA</i>-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).
Dejan Juric, Kevin Kalinsky, Seock‐Ah Im, Eva Ciruelos, Giampaolo Bianchini, Carlos H. Barrios +9 more
2023· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrityconsensus · none
16
citations
affunlabeled
Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.
Sunil Verma, Joyce O’Shaughnessy, Howard A. Burris, Mario Campone, Emilio Alba, David Chandiwana +4 more
2017· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
16
citations
affunlabeled
Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with <i>PIK3CA-</i>mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
Hope S. Rugo, Manuel Ruíz Borrego, Stephen Chia, Dejan Juric, Nicholas C. Turner, Pamela Drullinsky +6 more
2019· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrityconsensus · none
15
citations
affunlabeled
Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups
HS Rugo, RS Finn, Véronique Dièras, Johannes Ettl, Oleg Lipatov, Anil A. Joy +8 more
2018· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
15
citations
← previousnext →

How this was built: Screen · Findings · About